@COVaRiPAD Profile picture

COVaRiPAD

@COVaRiPAD

COVID-19 Vaccine Responses in Patients with Autoimmune Disease Collaborative. Effort between @WUSTLmed and @UCSFMed #COVaRiPAD

Joined April 2021
Similar User
Jeffrey Sparks MD MMSc photo

@jeffsparks

David Leverenz, MD photo

@DavidLeverenz

Alfred Kim (moving to Bluesky as alhkim) photo

@alhkim

WashU Rheumatology *Inactive photo

@WashUMedRheum

Michael Paley, M.D., Ph.D. (moving to @Bluesky) photo

@drmapaley

Lacey Feigl (moved to @Bluesky @LaceyFeigl) photo

@LaceyFeigl

Sambhawana Bhandari photo

@_Sambhawana

Naomi Patel (née Serling-Boyd) photo

@NaomiRheumMD

LSBC photo

@BarzolaLinda

Yvan Maque photo

@MaqueYvan

Pinned

On behalf of the entire #COVaRiPAD team, we are thrilled to announce our preprint reporting humoral responses after BOTH doses of mRNA-based SARS-CoV-2 vax in 133 pts w/ chronic inflammatory diseases (CID) and 53 immunocompetent controls: medrxiv.org/content/10.110….


Great talk by @alhkim today at the @WUSTL_Rheum Translational Research Conference on immunosupression and SARS-CoV-2 vaccination! Great work again by all of the collaborators (too many to tag)! @IbdWustl @WashUID @WUSTLneurosci @wusm_pathology @UCSFRheum #Research #COVID19

Tweet Image 1

COVaRiPAD Reposted

Congrats to @niti_pawar who led the effort (as a @UCSFMedicine med student!) on another #COVaRiPAD manuscript! Job well done by the entire team!

On behalf of the co-authors, I am delighted to present our observations from the #COVaRiPAD cohort examining longitudinal changes in patient-reported outcomes following SARS-CoV-2 vaccination in the immunosuppressed: onlinelibrary.wiley.com/doi/10.1002/ac…



COVaRiPAD Reposted

Another manuscript on longitudinal changes in PROS using PROMIS following SARS-CoV-2 vaccination, published from our group at the @COVaRiPAD cohort funded by @HelmsleyTrust 🧵 by 1st author @niti_pawar @UCSFMedicine 👇🏼

On behalf of the co-authors, I am delighted to present our observations from the #COVaRiPAD cohort examining longitudinal changes in patient-reported outcomes following SARS-CoV-2 vaccination in the immunosuppressed: onlinelibrary.wiley.com/doi/10.1002/ac…



COVaRiPAD Reposted

On behalf of the co-authors, I am delighted to present our observations from the #COVaRiPAD cohort examining longitudinal changes in patient-reported outcomes following SARS-CoV-2 vaccination in the immunosuppressed: onlinelibrary.wiley.com/doi/10.1002/ac…


COVaRiPAD Reposted

Whole lotta love for this project! Exciting to see this data shared at @DDWMeeting #DDW2022 #COVaRiPAD

Tweet Image 1
Tweet Image 2

COVaRiPAD Reposted

Thrilled to present our analysis of the relationship between the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine in immunosuppressed patients with chronic inflammatory disease in the @COVaRiPAD cohort, now out in @ACR_Journals: onlinelibrary.wiley.com/doi/10.1002/ac…


COVaRiPAD Reposted

We have a long way to go but we won’t stop advocating for our patients. Just like our very own @alhkim who was interviewed for this article! Thank you, @edyong209 for writing this important piece! theatlantic.com/health/archive… @WUDeptMedicine #immunocompromised #COVIDvaccine


COVaRiPAD Reposted

@COVaRiPAD New @MedCellPress 👉 reduced neutraliz. abs with TNFi esp. against B.1.617.2 Delta virus 👉 Neut titers of all TNFi pts below threshold for antibody-mediated protection @5 months 👉 3rd mRNA vaccine dose boosted neut antibody titers > 16-fold. sciencedirect.com/science/articl…


COVaRiPAD Reposted

Now out in @MedCellPress from team @COVaRiPAD: Reduced Ab activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving TNFα inhibitors (cell.com/med/fulltext/S…). Thread below for details, but there's 1 new piece of data you'll want to see...

NEW PREPRINT FROM TEAM #COVaRiPAD: under the leadership of @MSDiamondlab & Rita Chen, those on TNFi monotherapy at higher risk of poor neutralization responses to B.1.617.2 (delta) variant at 3 & 5 mths post-vax, w/ poor Fc effector fxn capacity. 1/ medrxiv.org/content/10.110…



COVaRiPAD Reposted

Will provide an update tomorrow, including some interesting delta cross-neutralization data, for those interested: Abst # 0457 Plenary I 11:45 AM meet.acrconvergence.org/meetings/YQMF9… And gotta thank @drmapaley for introducing UpSet plots to me. #ACR21 #ACRambassador

Awesome to see COVaRiPAD make Year in Review! @alhkim FTW! Aside from the useful COVID information, I learned a new type of graph - an "Upset plot" (see below) Slick way to describe how upset you are by how many rx your patients are taking 😅 #ACR21 #ACRambassador #UpsetR

Tweet Image 1
Tweet Image 2
Tweet Image 3


COVaRiPAD Reposted

Some more #COVaRiPAD work presented at #ACR21: @monicayangMD, Abs # 0113 Epidemiology & Public Health Poster I: COVID-19 & Vaccination 11/6, 0730 EDT Niti Pawar, Abs # 1590 Patient Outcomes, Preferences, & Attitudes IV: COVID-19 11/9, 0730 EST #ACRambassador

Will provide an update tomorrow, including some interesting delta cross-neutralization data, for those interested: Abst # 0457 Plenary I 11:45 AM meet.acrconvergence.org/meetings/YQMF9… And gotta thank @drmapaley for introducing UpSet plots to me. #ACR21 #ACRambassador



COVaRiPAD Reposted

NEW PREPRINT FROM TEAM #COVaRiPAD: under the leadership of @MSDiamondlab & Rita Chen, those on TNFi monotherapy at higher risk of poor neutralization responses to B.1.617.2 (delta) variant at 3 & 5 mths post-vax, w/ poor Fc effector fxn capacity. 1/ medrxiv.org/content/10.110…


COVaRiPAD Reposted

This week's top story: Glucocorticoids, B-cell depleting therapies may dampen immune response to #COVID19 vaccines. Study by @alhkim @P_DeepakIBDMD @TheBcellArtist @drmapaley @CiorbaGI @JaneOHalloran1 & @COVaRiPAD team @AnnalsofIM @WUSTL_Rheum bit.ly/3BMJfic


COVaRiPAD Reposted

Really appreciate @annie3mer for highlighting our initial analyses from the @COVaRiPAD study in @stltoday And truly thank Melinda Freeman, one of our participants in the study for providing her thoughts also. stltoday.com/lifestyles/hea…


COVaRiPAD Reposted

Plus too many more to name. We’d also like to thank our wonderful participants that volunteered their time (and blood) to help us with this project!


COVaRiPAD Reposted

(1/2) Some great news for our #autoimmune patients! Check out @alhkim interview with @KMOV about the “COVaRiPAD” study results that were published. We are so proud of this paper and the huge effort of the 60+ people involved in its creation. @WUGastro @WashUNeurology @COVaRiPAD


COVaRiPAD Reposted

COVID-19 #vaccination elicited antibody responses in nearly nine out of 10 people with weakened immune systems ow.ly/XRwu50G18jk @alhkim @WUSTLMed @UCSFMedicine @WUSTL_Rheum; @WUSM_Pathology; @IBDWUSTL; @WUGastro; @WashUID; @WashUNeurology; @WashUGenetics; @WUSM_MolMicro

Tweet Image 1

Loading...

Something went wrong.


Something went wrong.